Introducing Agendia

Agendia is committed to improving the quality of life of people suffering from cancer through enabling effective personalized medicine.

The company is pioneering the development and commercialization of validated tests that assist healthcare professionals and pharmaceutical companies to determine the diagnosis, prognosis and therapeutic responsiveness of cancers in individual patients.

A growing pipeline

Established in 2003, Agendia has already introduced three tests to the market. Since 2003, the DiscoverPrint service has been offered to pharmaceutical companies focusing on the development of cancer therapeutics, enabling them to select the most appropriate candidates for clinical trials of personalized therapeutics.

In 2004, Agendia became the first company to commercialize a prognostic test that predicts the risk of breast cancer recurrence (MammaPrint). The company also introduced CupPrint, a test to identify the origin of a metastasis when the location of the primary tumor is unknown, so called “Cancer of Unknown Primary”.

In 2007, MammaPrint became the first in vitro Diagnostic Multivariate Index Assay (IVDMIA) to acquire clearance from the US Food and Drug Administration (FDA). Agendia recently presented its new colon cancer prognosis profile, ColoPrint, which is currently undergoing further validation in the anticipation of developing a test to predict the likelihood of the cancer spreading at an early stage in the disease.

Leveraging the benefits of gene expression profiling
- microarray technology – and collaboration

The leaders of Agendia are the inventors and initiators of diagnostic microarray testing - the technology which forms the basis for the company’s commercially available tests.
Clinically-relevant tumor gene expression profiles are established through in-house research, research collaborations and strategic alliances with leading academic institutes. In particular, Agendia has very close links, both geographically and collaboratively, with The Netherlands Cancer Institute.

Once validated, these profiles are used to develop commercially available tests utilizing the microarray technology. Tests are currently performed in a high quality clinical laboratory at the company’s headquarters in Amsterdam, The Netherlands.

A growing business

Agendia working to develop further tests and applications and to market the current test portfolio globally through direct sales and an expanding distribution network. Both MammaPrint and CupPrint* are CE-marked and the company is ISO 17025 accredited and CLIA certified.
* not be sold in the USA